Výsledky vyhledávání - "Steve A Castillo"

Long-Term Safety and Tolerability of the Lamivudine/Abacavir Combination as Components of Highly Active Antiretroviral Therapy

Autor: Steve A Castillo, Jaime E Hernandez, Cindy H Brothers

Publikováno v: Drug Safety. 29:811-826

Background: Numerous large, long-term clinical trials have assessed the safety and efficacy of the two antiretroviral nucleoside analogs lamivudine and abacavir as components of highly active antiretroviral therapy for the treatment of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e478a607dfa86beb317b0209a7dbb1
https://doi.org/10.2165/00002018-200629090-00005

Zobrazit plný text záznamu

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study

Autor: Pedro Cahn, Ziagen Once-Daily in Antiretroviral Combination Therapy (Cna ) Study Team, David N Gordon, Edwin DeJesus, Henry Zhao, Charles Craig, Steve A. Castillo, Trevor Scott, Graeme Moyle

Publikováno v: Journal of acquired immune deficiency syndromes (1999). 38(4)

The long intracellular half-life of abacavir (ABC) supports its once-daily use, and this would be expected to simplify treatment if ABC could be given as part of a complete once-daily regimen. A randomized double-blind clinical trial compared the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bdd08959ecd9b836bf05da4fd75e4e5
https://pubmed.ncbi.nlm.nih.gov/15764958

Zobrazit plný text záznamu

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial

Autor: Shannon Schrader, Sam J. Madison, Charles Farthing, Denise D Shortino, Deborah A. Thomas, Beatriz Grinsztejn, Debra Mccarty, Kevin Gough, Edwin DeJesus, Michael Sension, Steve A. Castillo

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 39(3)

A randomized, double-blind, double-dummy controlled, multicenter trial was conducted that involved 554 antiretroviral-naive human immunodeficiency virus-infected adults (plasma HIV type 1 [HIV-1] RNA level, >or=400 copies/mL; CD4(+) cell count, >100

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5257c0d50aaf73f0a4a7d413c7a05469
https://pubmed.ncbi.nlm.nih.gov/15307010

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání